el laboratorio en el diagnóstico de las gammapatías monoclonales

(9) Perez-Persona E et al. New criteria to identify risk of progression in monoclonalgammopathy of uncertain significance and smoldering multiple myeloma based onmultiparameter flow cytometry analysis of bone marrow plasma cells. Blood.2007;110:2586 –2592.(10) Landgren O. Monoclonal gammopathy of undetermined significance andsmoldering myeloma: new insights into pathophysiology and epidemiology.Hematology Am Soc Hematol Educ Program. 2010;2010: 295-302.(11) García-Sanz R, González M, Ocio E. Macroglobulinemia de Waldemström.Haematologica. 2004;89:89-104.(12) Khosravi SHahi P, Del Castillo Rueda A., Díaz Muñoz de la Espada VM.Macroglobulinemia de Waldemström. An Med Interna. 2006;23:291-293.(13) Dispenzieri A. POEMS Syndrome. Hematology Am Soc Hematol Educ Program.2005: 360-367.(14) Rajkumar SV. Clinical features, laboratory manifestations, and diagnosis ofmultiple myeloma. UpToDate 2010. [actualizado 17 Mayo 2010; citado 1 Marzo2011]. Disponible en: http://www.uptodate.com(15) Sanz-Sabrafen J, Besses Raebel C, Vives Corrons J L. Hematología Clínica, 5.ªed. España:Elsevier S.A. 2006.(16) Wahner-Roedler DL, Kyle RA. Heavy chain diseases. Best Pract Res ClinHaematol.2005;18:729–746.(17) Rajkumar SV. Multiple mieloma: 2011 update on diagnosis, risk-stratification,and management. Am J Hematol. 2011;86:57-65.685